Preparations

Sofosbuvir (400 mg)

софоAn inhibitor of the viral polymerase NS5B, suppresses the replication (reproduction) of the virus hepatitis C. An analog Sovaldi ™

 

Annotation
View certificate

Asking price

Sofosbuvir (400 mg) is a nucleotide analogue used with other medicines (such as Declarewar, Ledipasvir) for the treatment of hepatitis C. Sofosbuvir inhibits RNA polymerase used by the hepatitis C virus to copy its own RNA. Sofosbuvir is intended for the treatment of HCV – 1, 2, 3 and 4 genotypes.

On the world market this drug was presented in 2013.

The advantages of the drug Sofosbuvir compared with the analogs are:

– higher efficiency;

– fewer side effects;

– shorter duration of the therapy.

Velpatasvir

ледиNS5V inhibits polymerase, thereby interrupts the replication of the viral genome.
It is used for the treatment of chronic hepatitis C genotypes 1, 2, 3, 4, 5 and 6. It is used as part of combination therapy for chronic hepatitis C.
In combination with sofosbuvir (Sofosbuvir) sustained virological response after 12 weeks of treatment, a total of up to 98% of patients (genotype 2.4 and 6 -100%).
Annotation

View certificate

Asking price

Daclatasvir (60 mg)

даклViral protein NS5A inhibitor does not come from the virus-infected cells in the blood, thus possible to prevent spread of the virus in the body. The analogue Daklinza ™, Aurhep

 

Annotation
View certificate

Asking price

Daclatasvir (60 mg) is an inhibitor of viral protein NS5A. Daclatasvir blocks virus HCV in cells, thereby preventing its reproduction. You should emphasize the fact that the application of Daclatasvir outside the complex therapy is not effective. For effective antiviral therapy of Daclatasvir is used with other antiviral drugs, for example, Sofosbuvir.

Ledipasvir

леди
Inhibitor of viral NS5A protein. Ledipasvir blocks the HCV virus in cells, thereby inhibiting its reproduction. Application Ledipasvira is complex therapy is not effective. To be effective, antiviral treatment is applied with Ledipasvir sofosbuvir.

The approved scheme sofosbuvir + Ledipasvir intended for the treatment of hepatitis C – genotype 1. In 96-99% of patients who underwent the first 12-week course and sofosbuvir Ledipasvira, sustained virologic response was seen.

.

Annotation
View certificate
Asking price